Analyst Ratings For AstraZeneca plc (LON:AZN)
Today, Shore Capital reiterated its Sell rating on AstraZeneca plc (LON:AZN).
There are 4 sell ratings, 9 hold ratings, 10 buy ratings, 1 strong buy rating on the stock.
The current consensus rating on AstraZeneca plc (LON:AZN) is Hold (Score: 2.33) with a consensus target price of GBX 4,906.32 per share, a potential .
Some recent analyst ratings include
- 2/16/2017-Shore Capital Reiterated Rating of Sell.
- 2/8/2017-BNP Paribas Reiterated Rating of Neutral.
- 2/3/2017-Credit Suisse Group Reiterated Rating of Underperform.
About AstraZeneca plc (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Recent Trading Activity for AstraZeneca plc (LON:AZN)
Shares of AstraZeneca plc closed the previous trading session at 4,510.50 down -23.30 -0.51% with 1,858,146 shares trading hands.